4 quarters of 13F filings · Δ columns show change vs prior quarter
Quarter
Inst. Holders
Δ Holders
Ownership %
Δ Ownership
Total 13F Value
Δ Value
Q2 2026
102
+28%
81.40%
+12.98 pp
$893M
+24%
Q1 2026
80
+43%
68.42%
+18.59 pp
$720M
+105%
Q4 2025
56
+40%
49.83%
+30.84 pp
$350M
29%
Q3 2025
40
—
18.99%
—
$496M
—
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
How VOR Compares to Peers
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying VOR stock.
What percentage of VOR is owned by institutions?
Based on Q2 2026 13F filings, institutional ownership of Vor Biopharma Inc. stands at 81.4%, held across 102 reporting institutions.
Who is the largest institutional holder of VOR?
TCG Crossover Management, LLC is the largest reported institutional holder of VOR, with approximately 5,673,078 shares worth $0.10B as of Q2 2026.
Is VOR a hedge fund favorite?
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of VOR, including MILLENNIUM MANAGEMENT LLC.
What is VOR's Smart Money Score?
Our composite Smart Money Score for VOR is 65 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
How many institutions bought VOR this quarter?
38 institutions opened new positions in VOR during Q2 2026, while 17 fully exited. 45 added to existing positions and 18 trimmed.
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in VOR — a direct measure of their conviction.
VOR institutional ownership rose by 12.98 percentage points quarter-over-quarter, with a net change of +22 holders.
How concentrated is VOR ownership among the top holders?
The top 10 institutions account for 67.6% of all reported 13F value in VOR, and the top 25 account for 91.8%.
How does VOR compare to Immunology Biotech on institutional ownership?
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
Where does this VOR institutional ownership data come from?
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.